ArticleEmerging microbes & infections2025
A bivalent Mpox nanoparticle vaccine induces robust immune response and provides long-lasting protection against vaccinia virus challenge.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Toward Precision Vaccinology for Mpox: Rational Antigen Design, Next-Generation Platforms, and Immune Correlates of Protection.Tropical medicine and infectious disease · 2026Review
- MPXV H3L elicits broadly directed CD4 T cell responses in mpox patients and MVA vaccinees.Npj viruses · 2026Article
- HCMV-pUS2 Disrupts cGAS-STING Signaling through LMAN2L Degradation.PLoS pathogens · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2022 and 2024 monkeypox (mpox) outbreak highlighted the urgent need for effective, durable, and safe vaccines. In addition to the traditional smallpox vaccines that could bring cross-protection against mpox, mRNA and protein-subunit mpox vaccines were extensively studied after the outbreak of mpox. In this study, we engineered monkeypox virus (MPXV) nanoparticle vaccines by conjugating the M1R and A35R, two well-characterized protective antigens to the mi3 nanoparticle using the SpyTag-SpyCatcher system, generating mi3-M1R and mi3-A35R constructs. An equimolar mixture of mi3-M1R and mi3-A35R formed a bivalent MPXV vaccine candidate, termed mi3-AM. When administered intraperitoneally with the Mn adjuvant, the mi3-AM vaccine induced robust humoral and antigen-specific cellular immune responses. Notably, the mi3-AM vaccine provided long-lasting protection against a lethal challenge with vaccinia virus Western Reserve strain (VACV-WR) in mice. With ongoing mpox outbreaks and the limitations of current vaccines, our candidate represents a promising, deployable solution with potential to bridge existing gaps in global orthopoxvirus prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.